FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361959404> ?p ?o ?g. }

• W4361959404 abstract "<div>AbstractPurpose:<p>Nintedanib enhances the activity of chemotherapy in metastatic non–small cell lung cancer (NSCLC). In this phase I/II study, we assessed safety and efficacy of nintedanib plus neoadjuvant chemotherapy, using major pathologic response (MPR) as primary endpoint.</p>Patients and Methods:<p>Eligible patients had stage IB (≥4 cm)–IIIA resectable NSCLC. A safety run-in phase was followed by an expansion phase with nintedanib 200 mg orally twice a day (28 days), followed by three cycles of cisplatin (75 mg/m²), docetaxel (75 mg/m²) every 21 days plus nintedanib, followed by surgery. With 33 planned patients, the study had 90% power to detect an MPR increase from 15% to 35%.</p>Results:<p>Twenty-one patients (stages I/II/III, <i>N</i> = 1/8/12) were treated. One of 15 patients treated with nintedanib 200 mg achieved MPR [7%, 95% confidence interval (CI), 0.2%–32%]. Best ORR in 20 evaluable patients was 30% (6/20, 95% CI, 12%–54%). Twelve-month recurrence-free survival and overall survival were 66% (95% CI, 47%–93%) and 91% (95% CI, 79%–100%), respectively. Most frequent treatment-related grade 3–4 toxicities were transaminitis and electrolyte abnormalities. On the basis of an interim analysis the study was discontinued for futility. Higher levels of CD3⁺ and cytotoxic CD3⁺CD8⁺ T cells were found in treated tumors of patients who were alive than in those who died (652.8 vs. 213.4 cells/mm², <i>P</i> = 0.048; 142.3 vs. 35.6 cells/mm², <i>P</i> = 0.018).</p>Conclusions:<p>Although tolerated, neoadjuvant nintedanib plus chemotherapy did not increase MPR rate compared with chemotherapy historical controls. Additional studies of the combination in this setting are not recommended. Posttreatment levels of tumor-infiltrating T cells were associated with patient survival. Use of MPR facilitates the rapid evaluation of neoadjuvant therapies.</p><p><i>See related commentary by Blakely and McCoach, p. 3499</i></p></div>" @default.
• W4361959404 created "2023-04-05" @default.
• W4361959404 creator A5001098397 @default.
• W4361959404 creator A5009105122 @default.
• W4361959404 creator A5009466654 @default.
• W4361959404 creator A5010884206 @default.
• W4361959404 creator A5016730067 @default.
• W4361959404 creator A5018839123 @default.
• W4361959404 creator A5025095617 @default.
• W4361959404 creator A5028085268 @default.
• W4361959404 creator A5041062966 @default.
• W4361959404 creator A5043477787 @default.
• W4361959404 creator A5048380048 @default.
• W4361959404 creator A5049826084 @default.
• W4361959404 creator A5050140548 @default.
• W4361959404 creator A5057175032 @default.
• W4361959404 creator A5057281549 @default.
• W4361959404 creator A5058597594 @default.
• W4361959404 creator A5060288261 @default.
• W4361959404 creator A5062198066 @default.
• W4361959404 creator A5063752111 @default.
• W4361959404 creator A5067736041 @default.
• W4361959404 creator A5070156025 @default.
• W4361959404 creator A5074671045 @default.
• W4361959404 creator A5074756797 @default.
• W4361959404 creator A5074792755 @default.
• W4361959404 creator A5076621000 @default.
• W4361959404 creator A5077763767 @default.
• W4361959404 creator A5082839000 @default.
• W4361959404 date "2023-03-31" @default.
• W4361959404 modified "2023-09-25" @default.
• W4361959404 title "Data from A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non–Small Cell Lung Cancer" @default.
• W4361959404 doi "https://doi.org/10.1158/1078-0432.c.6528989" @default.
• W4361959404 hasPublicationYear "2023" @default.
• W4361959404 type Work @default.
• W4361959404 citedByCount "0" @default.
• W4361959404 crossrefType "posted-content" @default.
• W4361959404 hasAuthorship W4361959404A5001098397 @default.
• W4361959404 hasAuthorship W4361959404A5009105122 @default.
• W4361959404 hasAuthorship W4361959404A5009466654 @default.
• W4361959404 hasAuthorship W4361959404A5010884206 @default.
• W4361959404 hasAuthorship W4361959404A5016730067 @default.
• W4361959404 hasAuthorship W4361959404A5018839123 @default.
• W4361959404 hasAuthorship W4361959404A5025095617 @default.
• W4361959404 hasAuthorship W4361959404A5028085268 @default.
• W4361959404 hasAuthorship W4361959404A5041062966 @default.
• W4361959404 hasAuthorship W4361959404A5043477787 @default.
• W4361959404 hasAuthorship W4361959404A5048380048 @default.
• W4361959404 hasAuthorship W4361959404A5049826084 @default.
• W4361959404 hasAuthorship W4361959404A5050140548 @default.
• W4361959404 hasAuthorship W4361959404A5057175032 @default.
• W4361959404 hasAuthorship W4361959404A5057281549 @default.
• W4361959404 hasAuthorship W4361959404A5058597594 @default.
• W4361959404 hasAuthorship W4361959404A5060288261 @default.
• W4361959404 hasAuthorship W4361959404A5062198066 @default.
• W4361959404 hasAuthorship W4361959404A5063752111 @default.
• W4361959404 hasAuthorship W4361959404A5067736041 @default.
• W4361959404 hasAuthorship W4361959404A5070156025 @default.
• W4361959404 hasAuthorship W4361959404A5074671045 @default.
• W4361959404 hasAuthorship W4361959404A5074756797 @default.
• W4361959404 hasAuthorship W4361959404A5074792755 @default.
• W4361959404 hasAuthorship W4361959404A5076621000 @default.
• W4361959404 hasAuthorship W4361959404A5077763767 @default.
• W4361959404 hasAuthorship W4361959404A5082839000 @default.
• W4361959404 hasBestOaLocation W43619594042 @default.
• W4361959404 hasConcept C126322002 @default.
• W4361959404 hasConcept C143998085 @default.
• W4361959404 hasConcept C203092338 @default.
• W4361959404 hasConcept C2776256026 @default.
• W4361959404 hasConcept C2776694085 @default.
• W4361959404 hasConcept C2777714996 @default.
• W4361959404 hasConcept C2778239845 @default.
• W4361959404 hasConcept C2778341716 @default.
• W4361959404 hasConcept C2780171596 @default.
• W4361959404 hasConcept C2781190966 @default.
• W4361959404 hasConcept C31760486 @default.
• W4361959404 hasConcept C535046627 @default.
• W4361959404 hasConcept C61943457 @default.
• W4361959404 hasConcept C71924100 @default.
• W4361959404 hasConcept C90924648 @default.
• W4361959404 hasConceptScore W4361959404C126322002 @default.
• W4361959404 hasConceptScore W4361959404C143998085 @default.
• W4361959404 hasConceptScore W4361959404C203092338 @default.
• W4361959404 hasConceptScore W4361959404C2776256026 @default.
• W4361959404 hasConceptScore W4361959404C2776694085 @default.
• W4361959404 hasConceptScore W4361959404C2777714996 @default.
• W4361959404 hasConceptScore W4361959404C2778239845 @default.
• W4361959404 hasConceptScore W4361959404C2778341716 @default.
• W4361959404 hasConceptScore W4361959404C2780171596 @default.
• W4361959404 hasConceptScore W4361959404C2781190966 @default.
• W4361959404 hasConceptScore W4361959404C31760486 @default.
• W4361959404 hasConceptScore W4361959404C535046627 @default.
• W4361959404 hasConceptScore W4361959404C61943457 @default.
• W4361959404 hasConceptScore W4361959404C71924100 @default.
• W4361959404 hasConceptScore W4361959404C90924648 @default.
• W4361959404 hasLocation W43619594041 @default.
• W4361959404 hasLocation W43619594042 @default.
• W4361959404 hasOpenAccess W4361959404 @default.
• W4361959404 hasPrimaryLocation W43619594041 @default.
• W4361959404 hasRelatedWork W1973221089 @default.

• next